Navigation Links
Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Date:6/1/2009

>

Pixantrone is also now available in Europe on a named patient basis.

About Pixantrone

Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutic
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
2. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
3. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
7. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
8. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
9. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
10. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
11. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... A new report, commissioned by BioCrossroads and ... in-depth look at Indiana,s capital ... two different time frames: 1993 to 2002 and 2003 ... opportunities for investment growth.  The Life Science Innovation ... gains in innovation dollars as well as an increase ...
(Date:10/27/2014)... The new research report, “Gas ... Medium), Sub-type (Primary & Secondary), and End-User (Transmission ... & Power Generation) - Trends and Forecasts to ... analysis and forecasting of the market size. , ... 52 Figures spread through 146 Pages and in-depth ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 New ... SoundConnect , an industry leading unified communication ... partners and agents to deliver cloud-based audio and ... growth opportunities. , With SoundConnect’s Q4 incentive ... twenty-five video and/or web conferencing licenses sold, now ...
(Date:10/27/2014)... Investor-Edge has initiated coverage on ... NBIX ), Insmed Inc. (NASDAQ: INSM ), ... Corporation (NASDAQ: DYAX ), and Oncothyreon Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced ...
Breaking Biology Technology:New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4SoundConnect Unveils Q4 Partner Incentives 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... Over the past couple of decades, atomic force microscopy ... surfaces at astonishing resolutionsfractions of a nanometer in some ... below the surface? Researchers at the National Institute of ... right circumstances, surface science instruments such as the AFM ...
... ... Zeiss, a leading provider of microscopy solutions for a variety of ... These special web promotions are now being extended through to August ... stereomicroscopy instrument and a 5 percent discount for conversion of certain ...
... 2010 Financial Results , , , ... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) will host a conference call discussing ... Friday, July 30, 2010 at 11:00 AM ET ( 8:00 AM PT ... Dial-in information for the earnings call on July ...
Cached Biology Technology:Depth charge: Using atomic force microscopy to study subsurface structures 2Carl Zeiss Offers Online Promotions – Discounts on Stereomicroscopy and Converting to 3D Imaging 2Carl Zeiss Offers Online Promotions – Discounts on Stereomicroscopy and Converting to 3D Imaging 3Angiotech Pharmaceuticals Announces Conference Call and Webcast 2
(Date:10/29/2014)... the Society of Interventional Radiology,s (SIR) 40th ... one place where interventional radiologists, diagnostic radiologists, ... can come together to find the most ... discussed and tested. , "Connecting a ... SIR 2015 will feature essential updates on ...
(Date:10/29/2014)... Plants rely on sunlight to make their food, but they ... do. Recently, scientists discovered a group of molecules in plants ... in the Journal of the American Chemical Society , ... plant sunscreens work. , Timothy Zwier and colleagues at Purdue ... to daily can cause serious damage to plant DNA and, ...
(Date:10/29/2014)... nanoparticles is all the rage. Thousands of scientists worldwide ... of whether titanium dioxide nanoparticles from sun creams can ... carbon nanotubes from electronic products are as hazardous for ... nanoparticles in food can get into the blood via ... research funds are flowing – and the number of ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3
... The Patagonian Hippidion horse genus and North American stilt-legged ... tree, according to a new article in the open ... Alan Cooper, and colleagues use ancient DNA to argue ... and that American stilt-legged horses were American endemics, not ...
... of Toronto have mapped the molecular details that show ... immortalizes cells and causes them to continuously grow, thereby ... virus (EBV) is one of the most common human ... certain b-cell cancers like Burkitt's lymphoma as well as ...
... there's a recent wiki article with more details . New ... rat? A Guinea pig? Try none of the above. , A ... rodent with stubby legs and a tail covered in dense hair. ... actually more like a guinea pig or chinchilla. But not quite. ...
Cached Biology News:Ancient DNA helps clarify the origins of two extinct New World horse species 2U of T researchers map role of Epstein-Barr virus in cancer 2Scientists discover odd-ball rodent 2
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
... triple quadrupole 1200L sets the new ... environment - incorporating the latest technologies ... liquid chromatography analytical needs. The ... the Transmission Quadrupole Analyzer provide superior ...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human GFR alpha-4 Affinity Purified Polyclonal Ab...
Biology Products: